Patients with Prior history of Herpes Zoster ophthalmicus at increased risk of Recurrence after Recombinant Zoster Vaccine: JAMA.
The use of the recombinant zoster vaccine (RZV) is currently advised for immunocompetent adults aged 50 years or more and for immunocompromised adults aged 19 years or more, as it is effective in preventing herpes zoster ophthalmicus (HZO). Nevertheless, concerns regarding the safety of RZV in individuals with a history of HZO persist. In the […]